BR112014028307A2 - método para identificar ligantes do receptor ahr tendo atividade terapêutica supressiva de sebo, e referidos ligantes - Google Patents

método para identificar ligantes do receptor ahr tendo atividade terapêutica supressiva de sebo, e referidos ligantes

Info

Publication number
BR112014028307A2
BR112014028307A2 BR112014028307A BR112014028307A BR112014028307A2 BR 112014028307 A2 BR112014028307 A2 BR 112014028307A2 BR 112014028307 A BR112014028307 A BR 112014028307A BR 112014028307 A BR112014028307 A BR 112014028307A BR 112014028307 A2 BR112014028307 A2 BR 112014028307A2
Authority
BR
Brazil
Prior art keywords
ligands
identifying
therapeutic activity
ahr receptor
suppressive therapeutic
Prior art date
Application number
BR112014028307A
Other languages
English (en)
Portuguese (pt)
Inventor
Hilaire Saurat Jean
Original Assignee
Thesan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thesan Pharmaceuticals Inc filed Critical Thesan Pharmaceuticals Inc
Publication of BR112014028307A2 publication Critical patent/BR112014028307A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/20Dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112014028307A 2012-05-15 2013-05-15 método para identificar ligantes do receptor ahr tendo atividade terapêutica supressiva de sebo, e referidos ligantes BR112014028307A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12168121.7A EP2664919A1 (fr) 2012-05-15 2012-05-15 Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique
PCT/IB2013/053979 WO2013171696A1 (en) 2012-05-15 2013-05-15 Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands

Publications (1)

Publication Number Publication Date
BR112014028307A2 true BR112014028307A2 (pt) 2017-07-18

Family

ID=46801377

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014028307A BR112014028307A2 (pt) 2012-05-15 2013-05-15 método para identificar ligantes do receptor ahr tendo atividade terapêutica supressiva de sebo, e referidos ligantes

Country Status (19)

Country Link
US (2) US9480674B2 (enExample)
EP (2) EP2664919A1 (enExample)
JP (1) JP6254580B2 (enExample)
KR (1) KR20150022827A (enExample)
CN (1) CN104471391B (enExample)
AU (1) AU2013261093A1 (enExample)
BR (1) BR112014028307A2 (enExample)
CA (1) CA2873191A1 (enExample)
CO (1) CO7240392A2 (enExample)
HK (1) HK1205252A1 (enExample)
IL (1) IL235449A (enExample)
IN (1) IN2014DN10283A (enExample)
MX (1) MX2014013925A (enExample)
NZ (1) NZ702357A (enExample)
PH (1) PH12014502548A1 (enExample)
RU (1) RU2014150505A (enExample)
SG (1) SG11201407405VA (enExample)
WO (1) WO2013171696A1 (enExample)
ZA (1) ZA201408826B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2082736A1 (fr) 2008-01-23 2009-07-29 Jean Hilaire Saurat Composition pharmaceutique à usage topique
EP3692999A1 (en) * 2012-03-17 2020-08-12 The Regents of the University of California Fast diagnosis and personalized treatments for acne
EP2664919A1 (fr) 2012-05-15 2013-11-20 Jean Hilaire Saurat Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique
WO2016022703A1 (en) * 2014-08-06 2016-02-11 Thesan Pharmaceuticals, Inc. Agonists of the ahr receptor pathway having sebosuppressive activity and a method for identifying said agonists
JP2016150916A (ja) * 2015-02-17 2016-08-22 株式会社マンダム 皮脂分泌抑制剤
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
CN109715179A (zh) 2016-04-21 2019-05-03 内科德生物群系公司 用于治疗皮肤病症的组合物和方法
US11596657B2 (en) 2016-10-04 2023-03-07 Institut National De La Recherche Agronomique Use of AhR agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders
EP3715471A1 (en) 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
EP3875098A1 (en) 2020-03-04 2021-09-08 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement Use of coprococcus bacteria for the treatment of metabolic syndrome and inflammatory bowel diseases
WO2023064489A1 (en) * 2021-10-14 2023-04-20 Galileo Biosystems, Inc. Aryl hydrocarbon receptor (ahr) modulators and therapeutic uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07501540A (ja) * 1991-11-25 1995-02-16 リチャードソン、ビックス、インコーポレーテッド 皮膚シワ及び/又は皮膚萎縮を調節するための組成物
BR9908870A (pt) * 1998-03-16 2000-11-21 Procter & Gamble Processos para regularizarem a aparência da pele
CA2408152A1 (en) * 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
US6902881B2 (en) * 2000-10-13 2005-06-07 President And Fellows Of Harvard College Compounds and methods for regulating cell differentiation
US20030166583A1 (en) * 2002-02-22 2003-09-04 Oliver Yoa-Pu Hu Dermal cytochrome P450 1A inhibitors and enhancers
EP1418164A1 (en) 2002-11-07 2004-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists
FR2849597B1 (fr) * 2003-01-08 2006-12-08 Oreal Composition cosmetique pour le soin des peaux grasses, contenant un acide gras carboxylique ou l'un de ses derives
CA2593140C (en) * 2005-01-05 2013-08-13 Oliver Yoa-Pu Hu Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (ugt2b)
US20060210515A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Hair growth formula
US20060210524A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Skin care composition
DE102005056890A1 (de) 2005-11-28 2007-05-31 Institut für Umweltmedizinische Forschung gGmbH Kosmetisches Verfahren zur Beeinflussung der Melaninbildung in der Haut
KR100798252B1 (ko) * 2006-01-18 2008-01-24 주식회사 엘지생활건강 c-Kit 활성 저해제, 피부미백제 및 이를 함유하는피부미백용 조성물
DE102006011747A1 (de) * 2006-03-13 2007-09-27 Symrise Gmbh & Co. Kg Dermatologische und/oder kosmetische Zubereitungen
EP1842541A1 (en) * 2006-03-29 2007-10-10 G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg Plant components and extracts and uses thereof
US20090208432A1 (en) 2006-05-03 2009-08-20 Symrise Gmbh & Co., Kg AH Receptor Antagonists
US20080317684A1 (en) * 2006-09-06 2008-12-25 Isw Group, Inc. Topical Compositions
EP2082736A1 (fr) 2008-01-23 2009-07-29 Jean Hilaire Saurat Composition pharmaceutique à usage topique
WO2011069860A1 (en) * 2009-12-08 2011-06-16 Chr. Hansen A/S Novel use for the treatment of metabolic endotoxemia
KR20110139397A (ko) * 2010-06-23 2011-12-29 건국대학교 산학협력단 다약제 내성 저해 활성을 갖는 5,6-벤조플라본 화합물, 그의 제조 방법 및 이를 유효성분으로 포함하는 다약제 내성 저해용 조성물
CN101953838A (zh) * 2010-08-13 2011-01-26 李岱 吴茱萸次碱用于治疗银屑病的应用
EP2664919A1 (fr) 2012-05-15 2013-11-20 Jean Hilaire Saurat Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique

Also Published As

Publication number Publication date
PH12014502548A1 (en) 2015-01-21
JP6254580B2 (ja) 2017-12-27
EP2664919A1 (fr) 2013-11-20
HK1205252A1 (en) 2015-12-11
IL235449A (en) 2017-07-31
JP2015523553A (ja) 2015-08-13
MX2014013925A (es) 2015-05-11
KR20150022827A (ko) 2015-03-04
EP2850429A1 (en) 2015-03-25
ZA201408826B (en) 2016-09-28
CO7240392A2 (es) 2015-04-17
SG11201407405VA (en) 2014-12-30
CA2873191A1 (en) 2013-11-21
CN104471391A (zh) 2015-03-25
RU2014150505A (ru) 2016-07-10
NZ702357A (en) 2016-10-28
IN2014DN10283A (enExample) 2015-08-07
AU2013261093A1 (en) 2014-12-18
CN104471391B (zh) 2016-12-07
US20170042856A1 (en) 2017-02-16
US9480674B2 (en) 2016-11-01
WO2013171696A1 (en) 2013-11-21
US20150057343A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
BR112014028307A2 (pt) método para identificar ligantes do receptor ahr tendo atividade terapêutica supressiva de sebo, e referidos ligantes
EP2961336A4 (en) DEVICE, METHOD AND SYSTEM FOR AUTOMATED, NON-INVASIVE CELL ACTIVITY TRACKING
BR302012004647S1 (pt) "configuração aplicada em suporte para uma escova de pele elétrica."
BR112015006652A2 (pt) método e sistema para procedimentos cosméticos de pele para uso doméstico.
IL238516A0 (en) System and methods for creating curved paths through bone and modulating nerves within the bone
EP2973121A4 (en) SYSTEMS AND METHOD FOR ANALYZING AND INDICATING HUMAN GENOME VARIATIONS ASSOCIATED WITH DISEASES
BR112015002868A2 (pt) dispositivos, sistemas e métodos para se engajar tecido
BRDI7106336S (pt) Configuração aplicada em retentor de segurança para coleta de sangue
EP2988678A4 (en) CABLE AND DOUBLE T BAR ACTIVE FOR SURGICAL STAPLER
BR112014005937A2 (pt) sondas extremamente articuladas com disposição de conexões antitorção, métodos para sua formação e métodos de condução de procedimentos médicos
BR112014007789A2 (pt) sistemas e métodos para análise biológica
EP2833971A4 (en) METHOD, SYSTEM AND USE OF THERAPEUTIC ULTRASOUND
EP2812022A4 (en) CANCER TREATMENT AND MONITORING METHODS USING OX40 AGONISTS
BR112014029563A2 (pt) método e sistema para análise tomográfia de detritos por computador com múltipla energia
BR112014025700A2 (pt) gerador cirúrgico para dispositivos ultrasônicos e eletrocirúrgicos
BR112013022900A2 (pt) aparelho, método e programa de computador de monitoramento para monitorar sinais fisiológicos
EP2750611A4 (en) Lateral retractor system and methods of use
EP2506208A4 (en) JUDICIAL SYSTEM, METHOD AND PROGRAM
BR112013002284A2 (pt) método de monitoramento cardíaco fetal, programa de computador e dispositivo para monitoramento cardíaco fetal ultrassônico
BR302013000342S1 (pt) Configuração aplicada em aplicador para maquiagem
BR302013001428S1 (pt) Configuração aplicada em almofada para dispositivo facial
BR112014015511A2 (pt) método para tingir as fibras queratínicas humanas e dispositivo
BRDI7102911S (pt) Configuração aplicada em conjunto de segurança para coleta de sangue
EP2726010A4 (en) TREATMENT TOOL, MANIPULATOR AND SURGICAL SUPPORT SYSTEM
BR112014033045A2 (pt) dispositivo e método para ligação de tecido

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2514 DE 12-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.